BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7903948)

  • 1. Familial ovarian cancer.
    Buller RE; Anderson B; Connor JP; Robinson R
    Gynecol Oncol; 1993 Nov; 51(2):160-6. PubMed ID: 7903948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
    Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
    Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
    Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
    Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic alterations in the genesis and development of ovarian cancer].
    Okamoto A; Yokoyama S; Terashima Y
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
    Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
    Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
    Aida H; Takakuwa K; Nagata H; Tsuneki I; Takano M; Tsuji S; Takahashi T; Sonoda T; Hatae M; Takahashi K; Hasegawa K; Mizunuma H; Toyoda N; Kamata H; Torii Y; Saito N; Tanaka K; Yakushiji M; Araki T; Tanaka K
    Clin Cancer Res; 1998 Jan; 4(1):235-40. PubMed ID: 9516977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer.
    Jolly KW; Malkin D; Douglass EC; Brown TF; Sinclair AE; Look AT
    Oncogene; 1994 Jan; 9(1):97-102. PubMed ID: 8302608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression and mutation of p53 in epithelial ovarian cancer.
    Marks JR; Davidoff AM; Kerns BJ; Humphrey PA; Pence JC; Dodge RK; Clarke-Pearson DL; Iglehart JD; Bast RC; Berchuck A
    Cancer Res; 1991 Jun; 51(11):2979-84. PubMed ID: 2032235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
    Hal DG; Stoica G
    Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer.
    Buller RE; Niemann T; Connor JP; Squatrito RC; Skilling JS; Anderson B
    Gynecol Oncol; 1995 Jan; 56(1):39-44. PubMed ID: 7821846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
    Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in the ovary.
    Berchuck A
    J Cell Biochem Suppl; 1995; 23():223-6. PubMed ID: 8747400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.